Virological outcomes of various first-line ART regimens in patients harbouring HIV-1 E157Q integrase polymorphism: a multicentre retrospective study

Association of demographics, HCV co‐infection, HIV‐1 subtypes and genetic clustering with late HIV diagnosis: a retrospective analysis from the Japanese Drug Resistance HIV‐1 Surveillance Network

(2023) Machiko Otani et al.   Journal of the International AIDS Society

Transmitted drug resistance to integrase based first-line HIV antiretroviral regimens in the Mediterranean Europe

(2022) Adolfo de Salazar et al.   CLINICAL INFECTIOUS DISEASES

Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults

(2022) Rajesh T. Gandhi et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Phylodynamic analysis reveals changing transmission dynamics of HIV-1 CRF01_AE in Japan from heterosexuals to men who have sex with men

(2021) Machiko Otani et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Emergence of Resistance in HIV-1 Integrase with Dolutegravir Treatment in a Pediatric Population from the IMPAACT P1093 Study

(2021) Cindy Vavro et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Predictors of virological failure and time to viral suppression of first line integrase inhibitor based antiretroviral treatment

(2020) Ashima Pyngottu et al.   CLINICAL INFECTIOUS DISEASES

Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in Cameroon

(2020) Alexandra Calmy et al.   Lancet HIV

Surveillance of transmitted drug resistance to integrase inhibitors in Spain: implications for clinical practice

(2019) Marta Alvarez et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Resistance Analysis of Bictegravir/Emtricitabine/Tenofovir Alafenamide in HIV-1 Treatment-Naïve Patients Through 48 Weeks

(2019) Rima K. Acosta et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

E157Q integrase strand-transfer inhibitor substitution in patients with acute/recent HIV infection

(2019) Juan Ambrosioni et al.   AIDS

Dolutegravir-Based or Low-Dose Efavirenz–Based Regimen for the Treatment of HIV-1

(2019)   NEW ENGLAND JOURNAL OF MEDICINE

Antiviral activity of HIV‐1 integrase strand‐transfer inhibitors against mutants with integrase resistance‐associated mutations and their frequency in treatment‐naïve individuals

(2019) Nicolas A. Margot et al.   JOURNAL OF MEDICAL VIROLOGY

Prevalence of Primary Drug Resistance Against HIV-1 Integrase Inhibitors in Canada

(2018) Hezhao Ji et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Phenotypic analysis of HIV-1 E157Q integrase polymorphism and impact on virological outcome in patients initiating an integrase inhibitor-based regimen

(2018) Charlotte Charpentier et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Drug resistance in B and non-B subtypes amongst subjects recently diagnosed as primary/recent or chronic HIV-infected over the period 2013–2016: Impact on susceptibility to first-line strategies including integrase strand-transfer inhibitors

(2017) Samantha Andreis et al.   Journal of Global Antimicrobial Resistance

Characteristics of Transmitted Drug-Resistant HIV-1 in Recently Infected Treatment-Naive Patients in Japan

(2016) Junko Hattori et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Polymorphic substitution E157Q in HIV-1 integrase increases R263K-mediated dolutegravir resistance and decreases DNA binding activity

(2016) Kaitlin Anstett et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Non-virological response to a dolutegravir-containing regimen in a patient harbouring a E157Q-mutated virus in the integrase region

(2015) F. Danion et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Primary resistance to integrase strand-transfer inhibitors in Europe: Table 1.

(2015) M. Casadellà et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study

(2015) Jean-Michel Molina et al.   Lancet HIV

Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study

(2013) Francois Raffi et al.   LANCET

Natural Polymorphisms of Human Immunodeficiency Virus Type 1 Integrase and Inherent Susceptibilities to a Panel of Integrase Inhibitors

(2009) A. Low et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Rapid selection and archiving of mutation E157Q in HIV-1 DNA during short-term low-level replication on a raltegravir-containing regimen

(2009) J. Ghosn et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial

(2009) Jeffrey L Lennox et al.   LANCET

jpHMM: Improving the reliability of recombination prediction in HIV-1

(2009) A.-K. Schultz et al.   NUCLEIC ACIDS RESEARCH

Drug Resistance Mutations for Surveillance of Transmitted HIV-1 Drug-Resistance: 2009 Update

(2009) Diane E. Bennett et al.   PLoS One

Mutations Associated with Failure of Raltegravir Treatment Affect Integrase Sensitivity to the Inhibitor In Vitro

(2008) I. Malet et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY